Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells | Zendy

Viola Baradari | Zendy

Open Access

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

Author(s) -

Viola Baradari

Publication year - 2007

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v13.i33.4458

Subject(s) - bortezomib , sorafenib , cancer research , histone deacetylase inhibitor , cell cycle , apoptosis , cell growth , proteasome inhibitor , chemistry , gemcitabine , biology , pharmacology , histone deacetylase , cancer , biochemistry , histone , hepatocellular carcinoma , immunology , multiple myeloma , genetics , gene

To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research